Lucid Diagnostics Inc. (NASDAQ: LUCD) Stock Competitors & Peer Comparison
See LUCD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LUCD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LUCD | $0.81 | +0.41% | 154.3M | -2.19 | -$0.37 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.95 | -0.03% | 174.7B | 19.37 | $5.21 | +2.46% |
| MDT | $87.09 | -2.69% | 111.5B | 15.75 | $5.53 | +3.22% |
| SYK | $278.77 | +1.26% | 106.9B | 20.83 | $13.39 | +1.27% |
| BSX | $43.88 | -0.52% | 65.2B | 14.15 | $3.10 | N/A |
| EW | $88.08 | +1.44% | 50.7B | 32.63 | $2.70 | N/A |
| DXCM | $86.64 | -0.05% | 32.7B | 33.98 | $2.55 | N/A |
| GEHC | $66.46 | -0.48% | 30B | 14.57 | $4.56 | +0.21% |
| PHG | $24.77 | -1.35% | 24.2B | 14.15 | $1.75 | +3.94% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
LUCD vs BSX-PA Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
LUCD vs ABT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ABT trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ABT's P/E ratio is 19.37. In terms of profitability, LUCD's ROE is -4.04%, compared to ABT's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ABT's competition here
Medtronic plc (NYSE: MDT)
LUCD vs MDT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, MDT has a market cap of 111.5B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while MDT trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas MDT's P/E ratio is 15.75. In terms of profitability, LUCD's ROE is -4.04%, compared to MDT's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
LUCD vs SYK Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SYK has a market cap of 106.9B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SYK trades at $278.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SYK's P/E ratio is 20.83. In terms of profitability, LUCD's ROE is -4.04%, compared to SYK's ROE of +0.16%. Regarding short-term risk, LUCD is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
LUCD vs BSX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BSX has a market cap of 65.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BSX trades at $43.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BSX's P/E ratio is 14.15. In terms of profitability, LUCD's ROE is -4.04%, compared to BSX's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
LUCD vs EW Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, EW has a market cap of 50.7B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while EW trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas EW's P/E ratio is 32.63. In terms of profitability, LUCD's ROE is -4.04%, compared to EW's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
LUCD vs DXCM Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while DXCM trades at $86.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas DXCM's P/E ratio is 33.98. In terms of profitability, LUCD's ROE is -4.04%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, LUCD is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
LUCD vs GEHC Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while GEHC trades at $66.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas GEHC's P/E ratio is 14.57. In terms of profitability, LUCD's ROE is -4.04%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
LUCD vs PHG Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PHG trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PHG's P/E ratio is 14.15. In terms of profitability, LUCD's ROE is -4.04%, compared to PHG's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
LUCD vs ZBH Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ZBH trades at $91.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ZBH's P/E ratio is 10.77. In terms of profitability, LUCD's ROE is -4.04%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
LUCD vs ABMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LUCD's ROE is -4.04%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
LUCD vs SWAV Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LUCD's ROE is -4.04%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LUCD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
LUCD vs PEN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PEN trades at $318.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PEN's P/E ratio is 83.26. In terms of profitability, LUCD's ROE is -4.04%, compared to PEN's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
LUCD vs SNN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SNN trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SNN's P/E ratio is 18.19. In terms of profitability, LUCD's ROE is -4.04%, compared to SNN's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
LUCD vs BIO-B Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, LUCD is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
LUCD vs ALGN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ALGN has a market cap of 10.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ALGN trades at $144.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ALGN's P/E ratio is 13.13. In terms of profitability, LUCD's ROE is -4.04%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, LUCD is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
LUCD vs BIO Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BIO trades at $379.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BIO's P/E ratio is 40.90. In terms of profitability, LUCD's ROE is -4.04%, compared to BIO's ROE of +0.03%. Regarding short-term risk, LUCD is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
LUCD vs GMED Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while GMED trades at $75.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas GMED's P/E ratio is 17.06. In terms of profitability, LUCD's ROE is -4.04%, compared to GMED's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
LUCD vs BRKR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BRKR trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BRKR's P/E ratio is 32.42. In terms of profitability, LUCD's ROE is -4.04%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, LUCD is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
LUCD vs BRKRP Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BRKRP trades at $470.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BRKRP's P/E ratio is 256.72. In terms of profitability, LUCD's ROE is -4.04%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, LUCD is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BRKRP's competition here
Masimo Corporation (NASDAQ: MASI)
LUCD vs MASI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas MASI's P/E ratio is 44.43. In terms of profitability, LUCD's ROE is -4.04%, compared to MASI's ROE of +0.09%. Regarding short-term risk, LUCD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
LUCD vs GKOS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, GKOS has a market cap of 9.4B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while GKOS trades at $158.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas GKOS's P/E ratio is -184.34. In terms of profitability, LUCD's ROE is -4.04%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, LUCD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
LUCD vs PODD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PODD trades at $132.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PODD's P/E ratio is 22.63. In terms of profitability, LUCD's ROE is -4.04%, compared to PODD's ROE of +0.27%. Regarding short-term risk, LUCD is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
LUCD vs HAE Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while HAE trades at $105.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas HAE's P/E ratio is 21.13. In terms of profitability, LUCD's ROE is -4.04%, compared to HAE's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
LUCD vs NARI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NARI's P/E ratio is -59.24. In terms of profitability, LUCD's ROE is -4.04%, compared to NARI's ROE of -0.00%. Regarding short-term risk, LUCD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
LUCD vs ITGR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ITGR trades at $126.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ITGR's P/E ratio is 19.90. In terms of profitability, LUCD's ROE is -4.04%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, LUCD is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
LUCD vs LIVN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while LIVN trades at $76.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas LIVN's P/E ratio is 18.29. In terms of profitability, LUCD's ROE is -4.04%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
LUCD vs IRTC Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while IRTC trades at $114.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas IRTC's P/E ratio is -265.63. In terms of profitability, LUCD's ROE is -4.04%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, LUCD is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
LUCD vs AXNX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LUCD's ROE is -4.04%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
LUCD vs TMDX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while TMDX trades at $84.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas TMDX's P/E ratio is 42.68. In terms of profitability, LUCD's ROE is -4.04%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, LUCD is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
LUCD vs NEOG Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NEOG trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NEOG's P/E ratio is 45.46. In terms of profitability, LUCD's ROE is -4.04%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, LUCD is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
LUCD vs BFLY Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BFLY trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BFLY's P/E ratio is -37.90. In terms of profitability, LUCD's ROE is -4.04%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, LUCD is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
LUCD vs UFPT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while UFPT trades at $296.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas UFPT's P/E ratio is 30.33. In terms of profitability, LUCD's ROE is -4.04%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, LUCD is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
LUCD vs AXGN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AXGN trades at $42.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AXGN's P/E ratio is 111.68. In terms of profitability, LUCD's ROE is -4.04%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, LUCD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
LUCD vs INSP Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while INSP trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas INSP's P/E ratio is 32.26. In terms of profitability, LUCD's ROE is -4.04%, compared to INSP's ROE of +0.18%. Regarding short-term risk, LUCD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check INSP's competition here
NuVasive, Inc. (NASDAQ: NUVA)
LUCD vs NUVA Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LUCD's ROE is -4.04%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
LUCD vs ESTA Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ESTA trades at $63.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ESTA's P/E ratio is -50.56. In terms of profitability, LUCD's ROE is -4.04%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, LUCD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
LUCD vs NVCR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NVCR trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NVCR's P/E ratio is -12.30. In terms of profitability, LUCD's ROE is -4.04%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, LUCD is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
LUCD vs ATEC Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ATEC trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ATEC's P/E ratio is -172.83. In terms of profitability, LUCD's ROE is -4.04%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, LUCD is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
LUCD vs CNMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CNMD trades at $46.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CNMD's P/E ratio is 10.26. In terms of profitability, LUCD's ROE is -4.04%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
LUCD vs HSKA Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LUCD's ROE is -4.04%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LUCD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
LUCD vs IART Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while IART trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas IART's P/E ratio is 7.05. In terms of profitability, LUCD's ROE is -4.04%, compared to IART's ROE of -0.01%. Regarding short-term risk, LUCD is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
LUCD vs AVNS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AVNS's P/E ratio is 27.77. In terms of profitability, LUCD's ROE is -4.04%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, LUCD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
LUCD vs TNDM Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while TNDM trades at $16.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas TNDM's P/E ratio is -17.82. In terms of profitability, LUCD's ROE is -4.04%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, LUCD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
LUCD vs SILK Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SILK's P/E ratio is -18.96. In terms of profitability, LUCD's ROE is -4.04%, compared to SILK's ROE of -0.35%. Regarding short-term risk, LUCD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
LUCD vs AORT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AORT trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AORT's P/E ratio is 38.07. In terms of profitability, LUCD's ROE is -4.04%, compared to AORT's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
LUCD vs IRMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while IRMD trades at $86.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas IRMD's P/E ratio is 43.45. In terms of profitability, LUCD's ROE is -4.04%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, LUCD is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
LUCD vs FNA Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas FNA's P/E ratio is -19.83. In terms of profitability, LUCD's ROE is -4.04%, compared to FNA's ROE of -0.35%. Regarding short-term risk, LUCD is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
LUCD vs ENOV Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ENOV trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ENOV's P/E ratio is 5.29. In terms of profitability, LUCD's ROE is -4.04%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, LUCD is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
LUCD vs PRCT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PRCT trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PRCT's P/E ratio is -9.39. In terms of profitability, LUCD's ROE is -4.04%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, LUCD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
LUCD vs LMRI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, LMRI has a market cap of 985.8M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while LMRI trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas LMRI's P/E ratio is -19.96. In terms of profitability, LUCD's ROE is -4.04%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, LUCD is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
LUCD vs BVS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BVS has a market cap of 948.5M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BVS trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BVS's P/E ratio is 18.42. In terms of profitability, LUCD's ROE is -4.04%, compared to BVS's ROE of +0.28%. Regarding short-term risk, LUCD is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
LUCD vs CBLL Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CBLL has a market cap of 943.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CBLL trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CBLL's P/E ratio is -14.12. In terms of profitability, LUCD's ROE is -4.04%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, LUCD is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
LUCD vs BBNX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BBNX has a market cap of 873.2M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BBNX trades at $19.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BBNX's P/E ratio is -11.76. In terms of profitability, LUCD's ROE is -4.04%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, LUCD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check BBNX's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
LUCD vs SIBN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SIBN has a market cap of 849.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SIBN trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SIBN's P/E ratio is -56.32. In terms of profitability, LUCD's ROE is -4.04%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, LUCD is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
LUCD vs CSII Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CSII's P/E ratio is -20.83. In terms of profitability, LUCD's ROE is -4.04%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
LUCD vs INMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, INMD has a market cap of 817.4M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while INMD trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas INMD's P/E ratio is 9.88. In terms of profitability, LUCD's ROE is -4.04%, compared to INMD's ROE of +0.12%. Regarding short-term risk, LUCD is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
LUCD vs VREX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while VREX trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas VREX's P/E ratio is 19.44. In terms of profitability, LUCD's ROE is -4.04%, compared to VREX's ROE of +0.05%. Regarding short-term risk, LUCD is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
LUCD vs AHCO Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AHCO has a market cap of 771.4M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AHCO trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AHCO's P/E ratio is 11.57. In terms of profitability, LUCD's ROE is -4.04%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, LUCD is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AHCO's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
LUCD vs CTKB Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CTKB has a market cap of 743.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CTKB trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CTKB's P/E ratio is -30.51. In terms of profitability, LUCD's ROE is -4.04%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, LUCD is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CTKB's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
LUCD vs AVR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, AVR has a market cap of 738M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while AVR trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas AVR's P/E ratio is -3.91. In terms of profitability, LUCD's ROE is -4.04%, compared to AVR's ROE of -0.78%. Regarding short-term risk, LUCD is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check AVR's competition here
Surmodics, Inc. (NASDAQ: SRDX)
LUCD vs SRDX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SRDX's P/E ratio is -34.66. In terms of profitability, LUCD's ROE is -4.04%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
LUCD vs KIDS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, KIDS has a market cap of 584.6M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while KIDS trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas KIDS's P/E ratio is -19.29. In terms of profitability, LUCD's ROE is -4.04%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, LUCD is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
LUCD vs APEN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas APEN's P/E ratio is -9.43. In terms of profitability, LUCD's ROE is -4.04%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
LUCD vs SSII Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SSII's P/E ratio is -48.17. In terms of profitability, LUCD's ROE is -4.04%, compared to SSII's ROE of -0.27%. Regarding short-term risk, LUCD is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check SSII's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
LUCD vs PACB Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PACB has a market cap of 568.4M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PACB trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PACB's P/E ratio is -4.46. In terms of profitability, LUCD's ROE is -4.04%, compared to PACB's ROE of -49.62%. Regarding short-term risk, LUCD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PACB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
LUCD vs DCTH Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, DCTH has a market cap of 547.2M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while DCTH trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas DCTH's P/E ratio is 1585.00. In terms of profitability, LUCD's ROE is -4.04%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, LUCD is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
LUCD vs ZIMV Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, LUCD's ROE is -4.04%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, LUCD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ZIMV's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
LUCD vs SGHT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SGHT has a market cap of 508.7M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SGHT trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SGHT's P/E ratio is -16.70. In terms of profitability, LUCD's ROE is -4.04%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, LUCD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
LUCD vs TCMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, TCMD has a market cap of 508.2M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while TCMD trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas TCMD's P/E ratio is 20.86. In terms of profitability, LUCD's ROE is -4.04%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, LUCD is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
LUCD vs CERS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CERS has a market cap of 497.8M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CERS trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CERS's P/E ratio is -82.06. In terms of profitability, LUCD's ROE is -4.04%, compared to CERS's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
LUCD vs NPCE Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NPCE has a market cap of 475.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NPCE trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NPCE's P/E ratio is -24.46. In terms of profitability, LUCD's ROE is -4.04%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, LUCD is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
LUCD vs SENS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SENS has a market cap of 420M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SENS trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SENS's P/E ratio is -4.51. In terms of profitability, LUCD's ROE is -4.04%, compared to SENS's ROE of -1.66%. Regarding short-term risk, LUCD is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
LUCD vs OFIX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, OFIX has a market cap of 394.1M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while OFIX trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas OFIX's P/E ratio is -6.35. In terms of profitability, LUCD's ROE is -4.04%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, LUCD is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
LUCD vs CLPT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CLPT has a market cap of 353M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CLPT trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CLPT's P/E ratio is -9.97. In terms of profitability, LUCD's ROE is -4.04%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, LUCD is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check CLPT's competition here
CapsoVision, Inc. (NASDAQ: CV)
LUCD vs CV Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CV has a market cap of 334.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CV trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CV's P/E ratio is -10.62. In terms of profitability, LUCD's ROE is -4.04%, compared to CV's ROE of -1.78%. Regarding short-term risk, LUCD is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
LUCD vs SMLR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas SMLR's P/E ratio is 3.92. In terms of profitability, LUCD's ROE is -4.04%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, LUCD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
LUCD vs TMCI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, TMCI has a market cap of 299.7M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while TMCI trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas TMCI's P/E ratio is -4.91. In terms of profitability, LUCD's ROE is -4.04%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, LUCD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
LUCD vs CATX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, CATX has a market cap of 298.8M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while CATX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas CATX's P/E ratio is -1.97. In terms of profitability, LUCD's ROE is -4.04%, compared to CATX's ROE of -0.42%. Regarding short-term risk, LUCD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check CATX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
LUCD vs RCEL Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, RCEL has a market cap of 297.1M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while RCEL trades at $11.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas RCEL's P/E ratio is -8.31. In terms of profitability, LUCD's ROE is -4.04%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, LUCD is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
LUCD vs INFU Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, INFU has a market cap of 263M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while INFU trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas INFU's P/E ratio is 31.78. In terms of profitability, LUCD's ROE is -4.04%, compared to INFU's ROE of +0.15%. Regarding short-term risk, LUCD is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INFU's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
LUCD vs TLSI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, TLSI has a market cap of 261.7M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while TLSI trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas TLSI's P/E ratio is -2.53. In terms of profitability, LUCD's ROE is -4.04%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, LUCD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check TLSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
LUCD vs MGRM Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas MGRM's P/E ratio is -12.00. In terms of profitability, LUCD's ROE is -4.04%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, LUCD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
LUCD vs ELMD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ELMD has a market cap of 232.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ELMD trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ELMD's P/E ratio is 21.47. In terms of profitability, LUCD's ROE is -4.04%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, LUCD is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
LUCD vs NVRO Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LUCD's ROE is -4.04%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LUCD is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
LUCD vs PROF Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, PROF has a market cap of 207.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while PROF trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas PROF's P/E ratio is -5.84. In terms of profitability, LUCD's ROE is -4.04%, compared to PROF's ROE of -0.56%. Regarding short-term risk, LUCD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
LUCD vs RXST Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, RXST has a market cap of 197.5M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while RXST trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas RXST's P/E ratio is -4.22. In terms of profitability, LUCD's ROE is -4.04%, compared to RXST's ROE of -0.17%. Regarding short-term risk, LUCD is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
LUCD vs BSGM Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas BSGM's P/E ratio is -5.81. In terms of profitability, LUCD's ROE is -4.04%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, LUCD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check BSGM's competition here
Quantum-Si incorporated (NASDAQ: QSI)
LUCD vs QSI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, QSI has a market cap of 189.5M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while QSI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas QSI's P/E ratio is -2.08. In terms of profitability, LUCD's ROE is -4.04%, compared to QSI's ROE of -0.47%. Regarding short-term risk, LUCD is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check QSI's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
LUCD vs MDGS Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas MDGS's P/E ratio is -0.27. In terms of profitability, LUCD's ROE is -4.04%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, LUCD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check MDGS's competition here
Quanterix Corporation (NASDAQ: QTRX)
LUCD vs QTRX Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, QTRX has a market cap of 172.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while QTRX trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas QTRX's P/E ratio is -1.44. In terms of profitability, LUCD's ROE is -4.04%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, LUCD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
LUCD vs FOCL Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, FOCL has a market cap of 170.2M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while FOCL trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas FOCL's P/E ratio is -4.39. In terms of profitability, LUCD's ROE is -4.04%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, LUCD is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
LUCD vs STIM Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, STIM has a market cap of 164.2M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while STIM trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas STIM's P/E ratio is -5.36. In terms of profitability, LUCD's ROE is -4.04%, compared to STIM's ROE of -1.51%. Regarding short-term risk, LUCD is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
LUCD vs QIPT Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas QIPT's P/E ratio is -15.87. In terms of profitability, LUCD's ROE is -4.04%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, LUCD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
LUCD vs INGN Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, INGN has a market cap of 145.4M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while INGN trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas INGN's P/E ratio is -5.90. In terms of profitability, LUCD's ROE is -4.04%, compared to INGN's ROE of -0.13%. Regarding short-term risk, LUCD is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
LUCD vs ICAD Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ICAD's P/E ratio is -20.37. In terms of profitability, LUCD's ROE is -4.04%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, LUCD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
LUCD vs HJLI Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas HJLI's P/E ratio is N/A. In terms of profitability, LUCD's ROE is -4.04%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, LUCD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check HJLI's competition here
electroCore, Inc. (NASDAQ: ECOR)
LUCD vs ECOR Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ECOR has a market cap of 98.1M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ECOR trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ECOR's P/E ratio is -6.48. In terms of profitability, LUCD's ROE is -4.04%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, LUCD is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for LUCD.Check ECOR's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
LUCD vs ASXC Comparison September 2026
Lucid Diagnostics Inc. (NASDAQ: LUCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCD stands at 154.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, LUCD is priced at $0.81 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCD currently has a P/E ratio of -2.19, whereas ASXC's P/E ratio is -1.12. In terms of profitability, LUCD's ROE is -4.04%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, LUCD is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for LUCD.Check ASXC's competition here